» Download Public Reports
26 reports
- Company report
- September 2012
- 2 pages
... With a multinational partner is already initiated. The development of a prescription drug cand is currently in progress. Advanced clinical development and commercialization is planned to be carried out ...
May 2012
... Industry. Demographic trends are expected to contribute to the growth in prescription drugs Consumption and to the increased use of pharmaceuticals as the primary intervention in individual healthcare ...
October 2012
... Conditions within the over-the-counter, medical food and prescription drug markets. About neptune technologies & bioressources inc. (Nasdaq:nept) (Tsx.V.Ntb) neptune is an industry-recognized leader ...
October 2012
... On treatments for chronic cardiovascular and cardiometabolic conditions within the over-the-counter, medical food and prescription drug markets. About neurobiopharm inc. Neurobiopharm is pursuing ...
November 2012
... Such as cardiometabolic disorders and cardiovascular diseases, and for neurodegenerative and inflammation related conditions. Acasti's lead prescription drug cand is capre , a purified high omega-3 phospholipid ...
January 2013
... Biopharm ), In which neptune respectively holds 57% and 96% of the voting rights, neptune is also pursuing opportunities in the medical food and prescription drug markets. Acasti and neurobiopharm respectively focus ...
November 2012
... Atherosclerotic conditions, such as cardiometabolic disorders and cardiovascular diseases, and for neurodegenerative and inflammation related conditions. Acasti's lead prescription drug cand is ca ...
June 2012
... Generally, as well as the reasons why prescription drugs are priced as they are both in the u.S. And canada. The paper will examine the safety and cost repercussions of a reimportation system ...